(Q37280739)

English

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

scientific article published on 15 June 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

peripheral neuropathy

1 reference

based on heuristic

inferred from title

5

object named as

Sagar Lonial

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

Kenneth C. Anderson

19

object named as

Kenneth C Anderson

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Paul G. Richardson

1

object named as

Paul G Richardson

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Nikhil V Munshi

14

object named as

Nikhil C Munshi

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Asher A Chanan Khan

4

object named as

Asher A Chanan-Khan

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Constantine S Mitsiades

3

object named as

Constantine Mitsiades

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Robert Schlossman

13

object named as

Robert L Schlossman

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dixie-Lee Esseltine

17

object named as

Dixie-Lee Esseltine

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

7

object named as

David E Avigan

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

2

object named as

Wanling Xie

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

6

object named as

Hani Hassoun

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Patrick Yung Wen

10

object named as

Patrick Y Wen

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Anne Louise Oaklander

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

David J Kuter

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Santosh Kesari

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Hannah R Briemberg

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

L Thompson Heffner

15

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Deborah Doss

16

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Edie Weller

18

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Anthony A Amato

20

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

15 June 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

21

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

3518-3525

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Expanding role of bortezomib in multiple myeloma: nursing implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

New drugs for myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

The emerging role of novel therapies for the treatment of relapsed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Neurological aspects of multiple myeloma and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

The proteasome: a suitable antineoplastic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Signatures of the immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

6 September 2017

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

14 September 2017

Primary dexamethasone treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

26 June 2018

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Bortezomib in combination with dexamethasone for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 September 2018

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

20 October 2018

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717758

3 December 2018

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NCCN clinical practice guidelines in oncology: multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neuropathy of multiple myeloma. An electrophysiological and histological study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The spectrum of peripheral neuropathy in myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Painful sensory neuropathy: prospective evaluation using skin biopsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cutaneous sensory nerve fibers are decreased in number after peripheral and central nerve damage

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NEUROLOGIC COMPLICATIONS OF MYELOMATOSIS

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19528374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.18.3087

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37280739&oldid=2215499843"